Angiodynamic Inc Dossier
Qualitative Analysis
Business overview
AngioDynamics, Inc. (NASDAQ: ANGO) is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving patient quality of life. Founded in Queensbury, New York, in 1988 and headquartered in Latham, New York, the company designs, manufactures, and sells minimally invasive medical, surgical, and diagnostic devices. AngioDynamics operates through two primary business segments: Med Tech and Med Device. The Med Tech segment represents the company's high-growth, high-margin innovation platforms, which include the Auryon peripheral atherectomy platform, the thrombus management platform (comprising the AlphaVac and AngioVac mechanical thrombectomy systems), and the NanoKnife irreversible electroporation (IRE) ablation system. The Med Device segment comprises foundational, steady-state product lines such as angiographic catheters, diagnostic and interventional guidewires, drainage catheters, and coaxial micro-introducer kits. The company sells its products in the United States through a direct sales force and internationally through a combination of direct sales and specialized distributors.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
AngioDynamics is executing a strategic shift away from lower-margin, commodity-based legacy medical devices toward high-growth, technology-driven Med Tech platforms. The core growth platforms driving this transformation are the Auryon peripheral atherectomy system, the thrombus management platform (AlphaVac and AngioVac), and the NanoKnife irreversible electroporation platform.
Expected impact: Accelerated top-line growth, expansion of gross margins (Med Tech gross margins are approximately 65.3% compared to 49.1% for Med Device), and improved long-term profitability.
The company is heavily investing in clinical trials to build robust, real-world clinical evidence supporting its Med Tech platforms. Key active studies include the AMBITION BTK trial (Auryon), the APEX-Return study (AlphaReturn/AlphaVac), the PAVE pilot study (AngioVac), and the newly approved RELIEF study (NanoKnife).
Expected impact: Securing expanded regulatory clearances, driving physician adoption, obtaining favorable reimbursement coverage, and establishing these platforms as standard-of-care treatments.
AngioDynamics is optimizing its manufacturing footprint and transitioning certain operations to improve efficiency. Additionally, the company is proactively managing supply chain risks by temporarily accelerating cash utilization to build inventory ahead of scheduled sterilization vendor maintenance shutdowns.
Expected impact: Mitigation of potential commercial disruptions and long-term gross margin stabilization despite temporary headwinds from tariffs and inflation.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
In February 2026, AngioDynamics and The PERT Consortium launched the ALPHA-PE Research Fund, an investigator-led initiative supporting independent pulmonary embolism (PE) research. The fund is designed to address critical evidence gaps in PE care, accelerating the generation of real-world clinical data to inform clinical decision-making and support the adoption of mechanical thrombectomy solutions like the AlphaVac system.
Terms: The fund will distribute competitive grants ranging from $50,000 to $750,000 over one to three years to selected investigators.